Want to see CTNM full AI Analyst Report?
CTNM Stock Chart & Stats
$14.06
$0.22(1.56%)
At close: 4:00 PM EDT
$14.06
$0.22(1.56%)
Day’s Range― - ―
52-Week Range$8.60 - $17.35
Previous CloseN/A
Volume15.74K
Average Volume (3M)170.88K
Market Cap
$646.71M
Enterprise Value$384.12
Total Cash (Recent Filing)$236.55M
Total Debt (Recent Filing)$6.57M
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Nov 11, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.73
Shares Outstanding32,958,633
10 Day Avg. Volume105,448
30 Day Avg. Volume170,880
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)1.21
Price to Sales (P/S)0.00
P/FCF Ratio-5.70
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$23.80Price Target Upside69.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.56
Revenue Forecast (FY)$8.26M
Bulls Say, Bears Say
Bulls Say
Low LeverageThe low debt burden and positive equity base provide financial flexibility to continue funding research and development. This reduces near-term solvency pressure and gives management more room to prioritize programs without relying entirely on debt financing.
PIPE-791 Development PotentialA lead asset with encouraging early clinical signals and potential applications in idiopathic pulmonary fibrosis and chronic pain could create meaningful future value. Its once-daily oral profile and possible combination use may support differentiation if later trials confirm efficacy.
Cash Runway And Capital DisciplineA projected runway through mid-2029 gives Contineum time to generate clinical readouts before requiring additional financing. Capital discipline may help preserve resources for the lead program and reduce the risk that near-term funding needs force unfavorable strategic or equity decisions.
Bears Say
No Recurring RevenueThe absence of current revenue leaves the company dependent on financing, licensing, or future product approvals to support operations. Persistent losses also show that the business model has not yet reached commercial validation, making long-term earnings visibility highly uncertain.
Heavy Cash BurnMaterial and worsening cash burn increases the amount of capital required to advance clinical programs and sustain operations. Even with a strong balance sheet and stated runway, continued losses could eventually lead to dilution or program prioritization if development timelines extend.
Pipeline ConcentrationDeferring CTX-343 and relying on a partner for PIPE-307 narrow the company’s internally funded development base. This increases dependence on PIPE-791 and external capital or partners, so setbacks in the lead program could have an outsized impact on future growth.
Contineum Therapeutics, Inc. Class A News
CTNM FAQ
What was Contineum Therapeutics, Inc. Class A’s price range in the past 12 months?
Contineum Therapeutics, Inc. Class A lowest stock price was $8.60 and its highest was $17.35 in the past 12 months.
What is Contineum Therapeutics, Inc. Class A’s market cap?
Contineum Therapeutics, Inc. Class A’s market cap is $646.71M.
When is Contineum Therapeutics, Inc. Class A’s upcoming earnings report date?
Contineum Therapeutics, Inc. Class A’s upcoming earnings report date is Nov 11, 2026 which is in 79 days.
How were Contineum Therapeutics, Inc. Class A’s earnings last quarter?
Contineum Therapeutics, Inc. Class A released its earnings results on Jul 30, 2026. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.449 by $0.049.
Is Contineum Therapeutics, Inc. Class A overvalued?
According to Wall Street analysts Contineum Therapeutics, Inc. Class A’s price is currently Undervalued.
Does Contineum Therapeutics, Inc. Class A pay dividends?
Contineum Therapeutics, Inc. Class A does not currently pay dividends.
What is Contineum Therapeutics, Inc. Class A’s EPS estimate?
Contineum Therapeutics, Inc. Class A’s EPS estimate is -0.45.
How many shares outstanding does Contineum Therapeutics, Inc. Class A have?
Contineum Therapeutics, Inc. Class A has 32,958,633 shares outstanding.
What happened to Contineum Therapeutics, Inc. Class A’s price movement after its last earnings report?
Contineum Therapeutics, Inc. Class A reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.449. Following the earnings report the stock price went down -1.651%.
Which hedge fund is a major shareholder of Contineum Therapeutics, Inc. Class A?
Currently, no hedge funds are holding shares in CTNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Contineum Therapeutics, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.80 (69.27% Upside)
$23.80 (69.27% Upside)
Hedge Fund Trend
Decreased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.24%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
36.90%
Trailing 12-Months
Company Description
Contineum Therapeutics, Inc. Class A
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
CTNM Stock 12 Month Forecast
Average Price Target
$23.80
▲(69.27% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Alpha Tau Medical Ltd
―
Immuneering
―
enGene Holdings
―
Ownership Overview
0.52% Insiders
8.92% Mutual Funds
42.69% Other Institutional Investors
38.06% Public Companies and
Individual Investors